Braveheart Bio Q2 2026 net loss $18.6M; cash $527.3M after IPO; Phase 3 trials advancing

Braveheart Bio, Inc.

Cash $122.8M at 6/30/26; $527.3M pro forma after Aug IPO net ~$404.5M; runway into 2029.
Net loss $15.0M; attributed to common stockholders $18.6M ($2.51/sh) vs $0.4M ($0.14/sh) in Q2 2025.
LIONHEART-HCM Phase 3 for oHCM initiated; first patient dosing expected 2026, interim results 2H 2027.
NOBLEHEART-HCM Phase 3 in nHCM expected to start 1H 2027 after Q2 Phase 2 data presented at HFA-ESC 2026.
R&D expense $11.1M (vs $0.0M), G&A $4.8M (vs <$0.1M) on advancement and public-company prep.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.